Klabion Uno

Clarithromycin, the active ingredient in Klabion Uno, is a macrolide antibiotic presented as an oral dosage form for systemic use. It acts by binding to the bacterial 50 S ribosomal subunit, thereby inhibiting protein synthesis. The drug is indicated for a variety of bacterial infections and is used in both adult and pediatric patients when appropriate.

GNH USA supplies Klabion Uno as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Clarithromycin is a macrolide antibiotic used to treat infections caused by susceptible bacteria.

- Community‑acquired pneumonia: eradicates the causative bacterial pathogens and improves respiratory symptoms. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Acute exacerbation of chronic bronchitis: shortens disease duration and relieves cough. - Skin and soft‑tissue infections: eliminates bacterial growth and promotes healing. - Helicobacter pylori eradication (in combination therapy): contributes to successful eradication regimens.

Clarithromycin may cause several adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered taste perception. - Headache: mild to moderate. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - QT prolongation: potential cardiac arrhythmias. - Severe allergic reactions: anaphylaxis or angioedema. - Clostridioides difficile‑associated diarrhea: severe colitis. - Hepatic dysfunction: elevated liver enzymes. - Stevens‑Johnson syndrome: severe skin reactions. - Cardiac toxicity: especially with interacting drugs.

Before prescribing clarithromycin, consider the following safety measures.

- Assess renal and hepatic function: adjust dose if impairment is present. - Avoid use in patients with known macrolide hypersensitivity: risk of allergic reactions. - Monitor QT interval in patients with cardiac risk factors: prevent arrhythmias. - Use with caution in pregnant or breastfeeding women: limited safety data. - Avoid concomitant use with strong CYP3A4 inhibitors: may increase drug levels. - Store at room temperature: keep in the original container, protect from moisture and light.

Clarithromycin can interact with several medications, requiring careful management.

Major Interactions (Avoid): - Other macrolides (e.g., erythromycin): additive risk of QT prolongation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise clarithromycin plasma concentrations. - Cisapride: increased risk of serious cardiac arrhythmias. - Pimozide: heightened potential for cardiac toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: possible increase in serum levels, watch for toxicity. - Statins (e.g., lovastatin): elevated risk of myopathy, monitor muscle symptoms.